Date: June 16, 2026
Merger Completion Details
Zydus Lifesciences Limited announced the completion of the merger of Zara Merger Sub Inc., a step-down wholly owned acquisition subsidiary of the Company, into Assertio Holdings Inc. The merger was consummated on June 16, 2026, resulting in Assertio becoming a wholly owned subsidiary of Zydus Lifesciences Limited. Following the merger, the common stocks of Assertio are no longer listed or traded on the Nasdaq Global Market.
Financial Consideration
The acquisition was completed through a cash offer of USD 23.50 per share, representing a total consideration of USD 166.33 million on a fully diluted basis. This includes payment of consideration deposited with the paying agent for common stock not tendered into the offer.
Business Overview of Assertio
Assertio Holdings Inc. is a U.S.-based specialty oncology pharmaceutical company with its registered office in Delaware, USA, and headquarters in Lake Forest, Illinois. The company has established commercial capability for marketing and distribution of differentiated oncology products. Its product ROLVEDON® (eflapegrastim xnst) is approved as Biologics License Application (BLA) by USFDA for long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer patients receiving myelosuppressive chemotherapy. ROLVEDON® is administered once per chemotherapy cycle in the oncology supportive care market.
Assertio's adjusted turnover for ROLVEDON® (surviving product, post asset sale of products on April 8, 2026, to Cosette Pharmaceuticals Inc.) for the calendar year ended December 31, 2025, was USD 68.23 million.
Transaction Details
Zara Merger Sub Inc. was incorporated on April 24, 2026, as an acquisition subsidiary specifically for this transaction. The transaction does not qualify as a related party transaction and was executed at arm's length. There is no change in the shareholding pattern of the listed entity as a result of this transaction.